Potential of Gene Therapy in Bone Marrow Transplantation |
| |
Authors: | Dr Sarah Marktel Chiara Bonini Claudio Bordignon |
| |
Affiliation: | Telethon Institute for Gene Therapy (TIGET), Ospedale S. Raffaele, Milan, Italy. |
| |
Abstract: | Gene therapy, initiated as a treatment for inherited disorders such as adenosine deaminase deficiency, is now a promising therapeutic strategy for malignancies and other acquired diseases. In particular, in the field of bone marrow transplantation (BMT) for haematological malignancies, the gene transfer of the suicide gene HSV-TK into donor lymphocytes allows control of the severe complication graft-versus-host disease (GvHD). The transfer of the HSV-TK suicide gene confers selective sensitivity to the drug ganciclovir, allowing in vivo elimination of the donor T-cells if severe GvHD occurs. In Italy, the first pilot study on delayed infusion of genetically engineered donor lymphocytes after T-depleted allogeneic BMT documented efficacy of engineered donor lymphocytes in terms of anti-tumour activity and efficiency of the suicide system. GvHD developed in 3 out of 8 patients and was successfully treated by ganciclovir administration. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|